Allergic disorders represent a serious public health problem in children. The chronic nature of these diseases and the fear of known side effects of synthetic drugs influence many families to seek complementary and alternative medicine. This review focuses on traditional Chinese medicine (TCM) herbal products and acupuncture for treating pediatric allergies.
Introduction
Over the past several decades, the number of individuals with atopic diseases such as asthma, atopic dermatitis and food allergies has increased dramatically in industrialized countries. Among children up to 4 years of age, the incidence of asthma has increased by 160%, and the incidence of atopic dermatitis has increased from twofold to three-fold [1] . Approximately 0.5-1% of the United States population is affected by peanut allergy (PNA), and the incidence has doubled in the past decade [2] . These figures demonstrate that allergic disorders in children are a serious public health problem and there is a need to find new treatments for these disorders. Current conventional medications for allergic disorders for children are not fully satisfactory. There are also concerns of known side effects of corticosteroids [3, 4] and long-term use of b-2 agonists. The chronic and potentially lifethreatening nature of these diseases and the lack of definitive preventive and curative therapies lead many families to seek complementary and alternative medicine (CAM) treatments. Although the results of surveys on CAM use by children vary between the studies, the reported rates by children with asthma ranges from 33 to 89% [5] . Because CAM therapies are generally considered to be well tolerated and effective for patients, and given the high rates of CAM use in children, healthcare providers need to educate themselves about these therapies, so they might better discuss the implications of using these therapies and potentially improve adherence to the prescribed medication regimen and improve allergy and asthma management [6 ] . A recent survey [7] reported that pediatricians have a positive attitude towards CAM. A majority believe that their patients are using CAM, and that asking about CAM should be part of routine medical history. They would also consider referring to a CAM practitioner and want more education on CAM.
with conventional medicine. However, what is considered CAM in one country may be considered as a part of standard treatment in another country or region [6 ] . For example, traditional Chinese medicine (TCM) has long human use experience in China and other Asian countries such as Korea and Japan and is part of mainstream medicine in these countries. In the United States and other Western countries, TCM is a major component of the CAM modality. TCM is a unique system of theory, diagnosis and treatments including herbal medicines, acupuncture and mind-body therapy. The National Institutes of Health (NIH)/National Center for Complementary and Alternative Medicine (NCCAM) defines TCM as whole medical systems (http://nccam.nih.gov/ health/backgrounds/wholemed.htm). TCM therapies are mainly provided by the licensed practitioners and are beginning to play a role in the United States healthcare system. Acupuncture needles have been approved by the US Food and Drug Administration (FDA) as medical devices (http://www.fda.gov/fdac/departs/596_upd.html), and the cost of acupuncture is covered by some insurance policies. However, traditional Chinese herbal medicines are viewed as dietary supplements in the United States and the cost is not covered by most insurance policies. This may contribute to the gap between scientific evidencebased medicine and human use-based practice. The NCCAM/NIH now supports clinical and basic research on CAM. In recent years, the FDA has provided guidance for investigating botanical drug products, including complex formulas containing several herbs, focusing on efficacy, safety and consistency [8] . NIH support and FDA guidelines will foster the development of TCM-derived botanical drugs in the United States. Thus, TCM products currently used as dietary supplements for asthma and allergy may be investigated as new botanical drugs. This communication focuses on controlled clinical trials of Chinese herbal medicines and acupuncture for asthma, allergic rhinitis and food allergy based on the available publications, including abstracts and review articles and updated research progress in the past 2 years.
Safety and efficacy of Chinese herbal therapy for childhood asthma
Asthma is a chronic inflammatory condition of the airways. It is believed that Th1 and Th2 responses are mutually antagonistic, such that they normally exist in equilibrium and cross-regulate each other. An optimum Th1-Th2 balance has been suggested as necessary to maintain healthy immune homeostasis. Loss of such balance has been hypothesized to underlie allergic asthma through a shift in immune responses from a Th1 (IFN-g) pattern toward a Th2 (IL-4, IL-5 and IL-13) profile, which promotes IgE production, eosinophilic inflammation, activation and survival and enhanced airway smooth muscle contractility [9] . A recent study [10] showed that low IFN-g production in the first year of life was a predictor of wheeze during childhood. Although corticosteroids improve asthma symptoms, they do not alter the progression of asthma or cure the disease [11] . In addition to known side effects, corticosteroid withdrawal is often accompanied by increased inflammation in bronchial biopsies and symptomatic disease relapse [12] . This has been suggested to be due to corticosteroidinduced overall suppression of both Th1 and Th2 responses. TCM formulas have been used for centuries to treat asthma, and there are a number of successful cases in children in the TCM literature [13] . A previous review by Bielory and Lupoli [14] provided some scientific evidence to support the use of TCM for asthma. Recently, Li [15] reviewed four double-blind, placebo-controlled studies of TCM herbal formulas for asthma. Among those, three studies namely modified Mai Men Dong Tang (mMMDT) by Hsu et al. [16] , Ding Chuan Tang (DCT) by Chan et al. [17] and STA-1 by Chang et al. [18] involved only pediatric asthma (Table 1 ) [19] [20] [21] [22] [23] . One study of antiasthma herbal medicine intervention (ASHMI) by Wen et al. [19] involved patients aged 18-60 years. On the basis of the definition of the pediatric population by NIH as aged 21 years and below, this study can be viewed as a study of older children and adults. There are also updated studies of ASHMI safety and tolerability and early efficacy in children and these will also be described below.
Antiasthma herbal medicine intervention
Wen et al. [19] reported the first double-blind, randomized, placebo-controlled trial investigating the efficacy and tolerability of an ASHMI. In this study, ASHMI (which contains three herbs, Table 1 ) was compared with oral prednisone therapy in 91 patients 18-60 years of age with moderate-to-severe asthma. Patients in the ASHMI group (45 patients) received oral ASHMI capsules [four capsules, three times daily (t.i.d.), 0.3 g/capsule] and placebo tablets similar in appearance to prednisone. Patients in the prednisone group (46 patients) received oral prednisone tablets [20 mg daily (q.d.) in the morning] and 'ASHMI placebo capsules' for 4 weeks. Treatment was administered daily over 4 weeks. This study found that following treatment, lung function [forced expiratory volume in 1 s (FEV1) and peak expiratory flow values] was significantly improved in both ASHMI (from 64.9 AE 63.6 to 84.2 AE 65.0; P < 0.001) and prednisone (from 65.2 AE 63.7 to 88.4 AE 68.0; P < 0.001) groups. The improvement was slightly but significantly greater in the prednisone group. To understand the mechanisms underlying ASHMI's clinical effects, immunological responses secondary to treatment were examined. Both ASHMI and prednisone decreased peripheral blood eosinophils, serum IgE and Th2 cytokine (IL-5 and IL-13) levels. Inhibition was greater in the prednisone group. However, unlike prednisone that suppressed IFN-g Table 1 Chinese herbal medicines and acupuncture for pediatric asthma and allergic rhinitis Herbal remedies Acupuncture mMMDT [16] STA-1 [18] ASHMI [19] DCT [17] NA [20] NA [21] Number of herbs [15] . Yin Tang (EX-2), the extraordinary point #2 (midpoint between the medial ends of the supraciliary arches); Ying Xiang (EX-8), the extraordinary point #8
(upper end of the nasolabial fold); Zu San Li (S36), the stomach channel point #36 (4 fingerbreadths below the depression lateral to the patella and 1 fingerbreadth lateral to the anterior border of the tibia).
secretion, ASHMI increased IFN-g secretion [19] . An additional unique finding was that, in contrast to prednisone, which decreased serum cortisol, patients in the ASHMI treatment group levels were within the normal range. This result might be attributed to glycyrrhizin (a component of Gan Cao), which affects the conversion of cortisol to cortisone by inhibition of 11-b-hydroxysteroid dehydrogenase enzyme activity [24] .
We recently completed a study to examine the safety, tolerability and immunological effects of complementary ASHMI administration to standard therapy only in children 5-14 years of age with persistent asthma, with or without allergic rhinitis, in China. Patients were randomly assigned to receive standard inhaled corticosteroid treatment (Budesonide -Pulmicort Turbohaler; Astra-Zeneca Pharmaceuticals, Wilmington, Delaware, USA) and ASHMI as complementary therapy (complementary ASHMI group, n ¼ 28) or inhaled corticosteroid treatment and placebo (standard group, n ¼ 28). Fifty-one patients completed the trial, including 26 patients in the complementary ASHMI group and 25 in the standard group. The results showed that ASHMI was well tolerated in children. As expected, both standard and complementary ASHMI groups significantly improved FEV1 and clinical symptoms. However, symptom score improvement was greater in the complementary ASHMI group than in the standard alone group, particularly in the nasal symptoms. Furthermore, complementary ASHMI group showed significantly greater reductions in serum total IgE (P < 0.05) and serum eosinophil cationic protein (P < 0.05) but higher serum IFN-g levels (P < 0.001) after 3 months of treatment as compared with the standard therapy (Wen et al. manuscript in preparation).
Modified Mai Men Dong Tang
Hsu et al. [16] tested mMMDT (five herbs, Table 1 ) treatment of persistent, mild-to-moderate asthma in children (Table 1 ). This 4-month trial included 100 asthmatics aged 5-18 years. The two active groups received 40 mg (40 patients) or 80 mg mMMDT (40 patients) for 4 months. The control group received placebo capsules (20 patients). Asthma medications were adjusted in a stepwise fashion equally in all three groups as follows: step 1, use of bronchodilator as needed; step 2, regular use of bronchodilator (theophylline or albuterol); step 3, regular use of two or three drugs (theophylline, albuterol and cromolyn); step 4, addition of beclomethasone delivered with a metered-dose inhaler or alternate day methylprednisolone; and step 5, addition of oral corticosteroids (>0.5 mg/kg per day, with tapering). Any acute exacerbation of asthma was treated as directed by the child's physician using tapered doses of oral methylprednisolone. The investigators reported that relative to baseline, significantly greater increases in FEV1 were demonstrated in both mMMDT-treated groups in comparison with the placebo group (P < 0.05 for both doses of mMMDT), but no dose response effect was found between the two mMMDT-treated groups. However, symptom scores were similarly improved in both mMMDT treatment groups. No drug-related adverse effects were reported. Blood tests and liver and kidney function test results were within normal ranges during the study. This study did not find a significant reduction of IgE by DCT as compared with placebo.
Ding Chuan Tang
Chan et al. [17] reported in a randomized, double-blind clinical trial that DCT, a nine-herb formula ( Table 1) , reduced airway hyperreactivity (AHR) in stabilized asthmatic children. This study enrolled children between 8 and 15 years of age diagnosed with mild-to-moderate persistent asthma. Patients were randomly allocated to receive 6.0 g DCT or placebo q.d. for 12 weeks. Fifty-two asthmatic children completed the study. Both groups received standard asthma management in a stepwise fashion (five steps) as outlined above in the study by Hsu et al. [16] . Twenty-eight patients were assigned to the treatment group and 24 to the placebo group. At the end of the treatment period, AHR determined by log PC 20 was significantly improved in the DCT group (0.51 AE 1.05 versus 0.26 AE 0.84 mg/ml; P ¼ 0.034). Clinical and medication scores showed improvement in the DCT group (P ¼ 0.004). The authors concluded that more stable airways were achieved by this add-on complementary therapy. This study did not find a significant reduction in IgE by DCT as compared with placebo.
STA-1
Chang et al. [18] reported results of a clinical evaluation of STA-1 and STA-2 herbal formulas ( Table 1) . STA-1 and STA-2 are combinations of mMMDT (10 herbs) and Lui-Wei-Di-Huang Wan (LWDHW, six herbs). STA-1 and STA-2 reportedly differ only in the preparation procedures of LWDHW. The six herbs in LWDHW were milled to a powder for STA-1, and extracted in boiling water for STA-2. Overall, 120 patients, 5-20 years of age with mild-to-moderate asthma were included in this study. Forty-four patients were treated with STA-1 at a dose of 80 g/kg per day and 40 were treated with STA-2 at a dose of 80 g/kg per day, and 16 patients received a placebo. Treatment was administered twice daily for 6 months. All patients were provided with asthma medications adjusted in a stepwise fashion as described above in the mMMDT study by Hsu et al. [16] . Completion rates were 88, 80 and 80% for STA-1, STA-2 and placebo, respectively. The results showed a statistically significant reduction in symptom scores, systemic steroid dose and total IgE and specific IgE levels in the STA-1 group. Furthermore, STA-1 improved pulmonary lung function FEV1 as compared with the placebo group. STA-2 treated patients showed no significant improvement in any parameter. The authors speculated that some as yet unknown heat-sensitive compounds in LWDHW possess anti-inflammatory activity. This study also found that total and specific IgE levels were significantly reduced by herbal therapy (STA-1) as compared with placebo treatment.
In summary, the above studies demonstrated consistent safety of herbal formulas for asthma used in children and some degree of positive clinical improvement. It should be pointed out that as standard therapy is sufficient to improve symptoms and lung function, TCM clinical efficacy as complementary therapy might have been masked by the corticosteroid effect during the short period of treatment and observation. Given the safety profile, long-term treatment should be considered. ASHMI has received FDA investigational new drug (IND) approval (IND 71 526) for phase I and II clinical trials for treating asthma. A phase I study has been completed. On the basis of clinical and laboratory test results, ASHMI was considered well tolerated [25] . A phase II study, involving 60 patients over 6-months' duration, is underway.
Safety and efficacy of acupuncture for asthma and allergic rhinitis in children
Acupuncture therapy is well accepted by the general population, including children. The FDA approved acupuncture needles as medical devices and regulates their use by licensed practitioners. Recently, Jindal et al. [26 ] reviewed 31 published journal articles, including 23 randomized controlled clinical trials and eight metaanalyses/systematic reviews addressing safety and efficacy of acupuncture in children. A very low risk was associated with acupuncture in pediatrics. Acupuncture seems to be most effective in preventing postoperativeinduced nausea and pain relief [26 ] . Controlled studies of acupuncture for asthma and allergy in children are limited; only two publications have been available in the past 5 years (Table 1 ). In the study by Stockert et al. [20] , 17 children aged 6-12 years with intermittent or mild persistent asthma were enrolled in a randomized, placebo-controlled, double blind pilot study. Eight patients received laser acupuncture for 10 weeks and probiotic treatment in the form of oral drops for 7 weeks. Nine patients in the control group were treated with a laser pen that did not emit laser light and were given placebo drops. Patients in the TCM group had fewer days of acute febrile infections when compared with the control group [1.14 (1.4) versus 2.66 (2.5) days; P ¼ 0.18]. There was no difference in lung function between the groups. In a study of acupuncture for allergic rhinitis by Ng et al. [21] , 72 children over the age of 6 years were randomized to receive either acupuncture or sham acupuncture for 8 weeks. During the 12-week follow-up period, the acupuncture group reported significantly better daily rhinitis scores (5.43 versus 7.19 in the sham group; P ¼ 0.03) and symptom-free days (12.7 versus 2.4 in the sham group; P ¼ 0.0001). However, no significant differences were found in relief medication use, nasal or blood eosinophil counts or serum IgE levels. Because of the popularity of acupuncture and some preliminary reported positive clinical results, controlled studies of acupuncture on asthma and allergy should be encouraged. However, given the nature of acupuncture practice, it might be difficult to apply double-blind and placebo (sham needles) controlled clinical study. There is a need to develop suitable methodology.
Development of herbal interventions for food allergy
Although tremendous strides have been made in food allergy awareness, there is no satisfactory therapy to prevent or reverse the disease. PNA imparts a significant psychological burden on the allergic individuals and their families [27] . An effective treatment would offer a lifealtering option for those affected. Studies of TCMs for food allergy are rare. Our group for the first time developed food allergy herbal formula-1 (FAHF-1) and then refined formula FAHF-2 by eliminating two herbs from FAHF-1. The following section summarizes both preclinical and preliminary clinical results of FAHF-2 studies.
Preclinical studies of efficacy and safety of food allergy herbal formula-2 on peanut and multiple food allergies FAHF-2, containing nine herb extracts, derived extracts of 11 herbs [28, 29] . Using a well established murine model PNA, we found that FAHF-2 completely blocked peanut-induced anaphylaxis when administered intragastrically during the development of peanut hypersensitivity [29] , or when administered after peanut hypersensitivity was fully established [30] . Recently, we showed that FAHF-2 provides persistent protection for almost a quarter of the mouse life span after a single course of treatment and also maintained the long-term beneficial immunomodulatory effect [31 ] . It has been shown that multiple food allergies are more common than single food allergy [32] . We recently developed a multiple food allergy model (peanut, egg and fish allergies) and tested the effect of FAHF-2 in this model. We showed that FAHF-2 provided complete protection from anaphylaxis to oral challenge with every allergen [33] .
The mechanisms underlying FAHF-2 protection against food-induced anaphylaxis are at multiple levels. We showed that FAHF-2 suppressed histamine release and reduced serum IgE but increased IgG2a [30] . The protective effect was associated with upregulation of Th1 and downregulation of Th2 cytokines. Thus, FAHF-2 exhibits an immunomodulatory effect, but not overall immunosuppressive effects. A similar immunomodulatory effect on peripheral blood mononuclear cells from children (aged 3-12 years) with PNAs has also been found in a study [34] in which FAHF-2 significantly reduced peanut-stimulated IL-5 production and increased IFN-g production. We also found that FAHF-2 inhibited Fce RI expression on mast cell and basophils in vivo, and inhibited mast cell degranulation in vitro [35] .
Clinical investigation of safety of food allergy herbal formula-2 for food allergy Given the excellent efficacy and safety profile in animal studies, FAHF-2 is an ideal candidate to develop a treatment for human food allergy. We received IND approval from the FDA, and then institutional review board (IRB) approval, and began a FAHF-2 clinical study in 2008. This is the first clinical investigation of a botanical drug for multiple persistent food allergy including peanut, and/or tree nut, fish and shellfish allergies and the first botanical drug trial that includes children. We now have completed a double-blind, dose escalation phase I study on 18 patients (12 patients in FAHF-2 and six in placebo) with peanut and other food allergies. The results showed that FAHF-2 is well tolerated (Wang et al. manuscript is in preparation). An extended 6-month phase I open label study is currently underway. After completion of this study, we will conduct a double-blind, placebocontrolled phase II study involving 120 patients.
Conclusion
Investigation of TCM herbal therapy for children with asthma is an active area of research. Several recent studies reported that these TCM formulas are well tolerated and had a positive effect on symptoms or lung function or both in children when used as monotherapy or complementary therapy. ASHMI also showed enhancement of IFN-g and serum cortisol levels, of potential benefit for asthma therapy. These results demonstrated that TCM herbal formulas have potential as CAM therapy for asthma treatment. Currently, a phase II study of ASHMI is ongoing in the United States to investigate whether ASHMI can reduce or replace corticosteroid use and assess long-term safety. FAHF-2 showed excellent long-term protection and beneficial immunomodulation effect in mice. ASHMI and FAHF-2 may prove to be the first generation of antiasthma and food allergy botanical drugs.
